Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Stony Brook University · State University of New York · +18 more institutions
Abstract
Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs.
We conducted two identical trials in different geographic regions to evaluate the safety and efficacy of raltegravir, as compared with placebo, in combination with optimized background therapy, in patients infected with HIV-1 that has triple-class drug resistance in whom antiretroviral therapy had failed. Patients were randomly assigned to raltegravir or placebo in a 2:1 ratio.
Citation impact
- FWCI
- 59.46
- Percentile
- 100%
- References
- 68
Authors
29- RTRoy T. SteigbigelCorresponding
Stony Brook University, State University of New York
- DADavid A. Cooper
National Centre for Clinical Research on Emerging Drugs, UNSW Sydney
- PKPrincy Kumar
Georgetown University Medical Center, Georgetown University
- JEJoseph Eron
University of North Carolina at Chapel Hill
- MSMauro Schechter
Universidade Federal do Rio de Janeiro
Topics & keywords
- Raltegravir
- Medicine
- Placebo
- Integrase inhibitor
- Internal medicine
- Discontinuation
- Viral load
- Liter
- Good health and well-being